Table 1

Patient demographics, clinical characteristics, and risk factors for FKS mutations

CharacteristicValue for groupP valuec
All patients (n = 39)FKS mutation (n = 7)No FKS mutation (n = 32)
No. (%) female31 (80)6 (86)25 (78)NS (1.00)
No. (%) of race
    White31 (80)6 (86)25 (78)NS (1.00)
    Black6 (15)1 (14)5 (16)
    Other2 (5)02 (6)
Median age in yrs (range)59 (22–88)63 (38–86)59 (22–88)NS (0.78)
No. (%) with type of IC
    Candidemia35 (90)5 (71)30 (94)NS (0.14)
    Abscess4 (10)2 (29)2 (6)
No. (%) with underlying condition
    Transplant14 (36)3 (43)11 (34)NS (0.69)
    Malignancy4 (10)04 (13)NS (1.00)
    GI diseasea14 (36)4 (57)10 (31)NS (0.23)
    Otherb7 (18)07 (22)NS (0.31)
No. (%) with GI surgery within 30 days of IC19 (49)7 (100)12 (38)0.003
No. (%) with TPN within 30 days of IC14 (36)6 (86)8 (25)0.005
No. (%) with prior echinocandin exposure13 (33)7 (100)6 (19)0.0001
No. (%) with prior azole exposure22 (56)5 (71)17 (53)NS (0.44)
Median days of prior echinocandin exposure (range)0 (0–117)64 (3–117)0 (0–20)<0.0001
Median days of prior azole exposure (range)6 (0–238)34 (0–100)5 (0–238)NS (0.09)
No. (%) with breakthrough IC
    Echinocandin4 (10)4 (57)00.0004
    Azole4 (10)04 (12)NS (1.00)
  • a GI disease includes short gut syndrome (n = 6), superior mesenteric artery syndrome (n = 2), abdominal fistula (n = 2), Crohn's disease (n = 1), diverticulitis (n = 1), necrotizing pancreatitis (n = 1), and liver cirrhosis (n = 1).

  • b Other underlying diseases include cardiovascular disease (n = 4), scleroderma (n = 1), and subarachnoid hemorrhage (n = 1); one patient had no significant past medical history.

  • c NS, not significant.